Business Wire

THE-UNNAMED-SOCIETY

25.10.2021 10:32:07 CEST | Business Wire | Press release

Share
The Unnamed Society Kicks Off Chapter II of The Book on The Art of Gifting at the 2021 SIAR International Watch Salon in Mexico City

Following through on its unique reinterpretation of Pancho Villa’s Bisley Colt introduced in 2019, The Unnamed Society takes the natural next step with Golden Boy , a reimagination of the legendary Winchester repeating rifle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005046/en/

Golden Boy is a work of art in form and function that adds a new dimension to a story that remains as fascinating and inspiring as ever, that of the Wild West and how it was won.

A true-to-the-legend reimagination of the iconic lever action rifle as a clock, its original loading and cocking mechanism rethought for winding the timekeeping calibre and setting the time. Holding – and beholding – this uniquely fascinating feat of engineering and artisanship evokes childhood dreams of a far-away age that ultimately helped shape our modern times. It can be displayed to great effect both on a desk, mantelpiece or on the wall.

Golden Boy doesn’t just tell time, but opens our imagination and takes us to where the buffalo once roamed and brave men and women struck out into the unknown, stood their ground and built a new world.

Today, the partnership between The Unnamed Society and the watch company l’Epée 1839 opens the second chapter of its unfolding history. With Golden Boy comes the second stunning creation imagined for those who set the bar for the Art of Gifting a bit higher than the rest.

Nicknamed the ‘Gun that Won the West,’ the Winchester Rifle remains one of the most iconic firearms of all time. For the gun that inspired Golden Boy , the year is 1866. It has the same dimensions and weight as the original, the same feel and heft.

Able to hold 15 rounds before having to reload, the original was not only much more practical than a single-shot rifle, but also allowed for excellent handling and accuracy without any significant training.

The watchmaker captures this defining movement of the hand as it loads the round and prepares the gun for firing: by having the clock mechanism wound – ‘loaded’ – in exactly the same way. By actioning the lever 15 times – as if loading 15 bullets one after the other – the mechanism is fully wound for a 7-day power reserve.

If marvel at the heart of each Golden Boy is only matched by the fact that it only comes as a bespoke creation, completely finished to the owner’s wishes. For the receiver, barrel and tubular magazine, the owner can choose from steel, 18K yellow, rose or white gold, and palladium. For the stock and forestock, from a selection of exotic woods.

Press Material: TUSSIAR2021 - Google Drive

Link:

ClickThru

Social Media:

https://www.facebook.com/theunnamedsociety

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye